-
1
-
2
Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer
Published 2023-06-01Subjects: Get full text
Article -
3
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
Published 2021-09-01Subjects: “…Donafenib…”
Get full text
Article -
4
-
5
Donafenib and GSK‐J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression
Published 2023-08-01Subjects: “…donafenib…”
Get full text
Article -
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
Integrated multi-omics demonstrates enhanced antitumor efficacy of donafenib combined with FADS2 inhibition in hepatocellular carcinoma
Published 2025-01-01Subjects: Get full text
Article -
14
Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
Published 2023-11-01Subjects: “…donafenib…”
Get full text
Article -
15
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
Published 2025-02-01Subjects: Get full text
Article -
16
VKH-like uveitis during donafenib therapy for hepatocellular carcinoma: a case report and review of the literature
Published 2024-07-01Subjects: Get full text
Article